Maintenance of intercellular coupling by the antiarrhythmic peptide rotigaptide suppresses arrhythmogenic discordant alternans
- PMID: 17982010
- DOI: 10.1152/ajpheart.01089.2006
Maintenance of intercellular coupling by the antiarrhythmic peptide rotigaptide suppresses arrhythmogenic discordant alternans
Abstract
Discordant action potential alternans creates large gradients of refractoriness, which are thought to be the mechanisms linking T-wave alternans to cardiac arrhythmogenesis. Since intercellular coupling acts to maintain synchronization of repolarization between cells, we hypothesized that intercellular uncoupling, such as during ischemia, would initiate discordant alternans and that restoration of intercellular coupling by the gap junction opener rotigaptide may provide a novel approach for suppressing arrhythmogenic discordant alternans. Optical mapping was used to record action potentials from ventricular epicardium of Langendorff-perfused guinea pig hearts. Threshold for spatially synchronized (i.e., concordant) alternans and discordant alternans was determined by increasing heart rate step-wise during 1) baseline, 2) treatment with rotigaptide or vehicle, and 3) global low-flow ischemia + rotigaptide or vehicle. Ischemia reduced the threshold for concordant alternans in both groups from 362 +/- 8 to 305 +/- 9 beats/min (P < 0.01) and for discordant alternans from 423 +/- 6 to 381 +/- 7 beats/min (P < 0.01). Interestingly, rotigaptide also increased the threshold for discordant alternans relative to vehicle both before (438 +/- 7 vs. 407 +/- 8 beats/min, P < 0.05) and during (394 +/- 7 vs. 364 +/- 9 beats/min, P < 0.05) ischemia. Rotigaptide increased conduction velocity and prevented conduction slowing and dispersion of repolarization during ischemia. Confocal immunofluorescence revealed that total connexin43 quantity and cellular distribution were unchanged before or after low-flow ischemia, with and without rotigaptide. However, connexin43 dephosphorylation in response to low-flow ischemia was significantly prevented by rotigaptide (15.9 +/- 7.0 vs. 0.3 +/- 6.4%, P < 0.001). These data suggest that intercellular uncoupling plays an important role in the transition from concordant to discordant alternans. By suppressing discordant alternans, repolarization gradients, and connexinx43 dephosphorylation, rotigaptide may protect against ischemia-induced arrhythmias. Drugs that selectively open gap junctions offer a novel strategy for antiarrhythmic therapy.
Comment in
-
Drug development for treatment of cardiac arrhythmias: targeting the gap junctions.Am J Physiol Heart Circ Physiol. 2008 Jan;294(1):H16-8. doi: 10.1152/ajpheart.01031.2007. Epub 2007 Sep 21. Am J Physiol Heart Circ Physiol. 2008. PMID: 17890421 No abstract available.
Similar articles
-
Drug development for treatment of cardiac arrhythmias: targeting the gap junctions.Am J Physiol Heart Circ Physiol. 2008 Jan;294(1):H16-8. doi: 10.1152/ajpheart.01031.2007. Epub 2007 Sep 21. Am J Physiol Heart Circ Physiol. 2008. PMID: 17890421 No abstract available.
-
Gap junction modifier rotigaptide decreases the susceptibility to ventricular arrhythmia by enhancing conduction velocity and suppressing discordant alternans during therapeutic hypothermia in isolated rabbit hearts.Heart Rhythm. 2016 Jan;13(1):251-61. doi: 10.1016/j.hrthm.2015.07.023. Epub 2015 Jul 15. Heart Rhythm. 2016. PMID: 26188250
-
Model-dependent effects of the gap junction conduction-enhancing antiarrhythmic peptide rotigaptide (ZP123) on experimental atrial fibrillation in dogs.Circulation. 2007 Jan 23;115(3):310-8. doi: 10.1161/CIRCULATIONAHA.106.665547. Epub 2007 Jan 15. Circulation. 2007. PMID: 17224477
-
Pharmacological modulation of gap junction function with the novel compound rotigaptide: a promising new principle for prevention of arrhythmias.Basic Clin Pharmacol Toxicol. 2007 Oct;101(4):215-30. doi: 10.1111/j.1742-7843.2007.00123.x. Basic Clin Pharmacol Toxicol. 2007. PMID: 17845503 Review.
-
Improving cardiac gap junction communication as a new antiarrhythmic mechanism: the action of antiarrhythmic peptides.Naunyn Schmiedebergs Arch Pharmacol. 2010 Mar;381(3):221-34. doi: 10.1007/s00210-009-0473-1. Epub 2009 Nov 27. Naunyn Schmiedebergs Arch Pharmacol. 2010. PMID: 19943035 Review.
Cited by
-
Characterization of gap junction remodeling in epicardial border zone of healing canine infarcts and electrophysiological effects of partial reversal by rotigaptide.Circ Arrhythm Electrophysiol. 2011 Jun;4(3):344-51. doi: 10.1161/CIRCEP.110.959312. Epub 2011 Apr 14. Circ Arrhythm Electrophysiol. 2011. PMID: 21493965 Free PMC article.
-
Should We Be Ablating the Kidneys or the Heart to Prevent Arrhythmias?JACC Basic Transl Sci. 2017 Apr 24;2(2):194-196. doi: 10.1016/j.jacbts.2017.03.006. eCollection 2017 Apr. JACC Basic Transl Sci. 2017. PMID: 30167566 Free PMC article.
-
Pharmacological modulation of connexin-formed channels in cardiac pathophysiology.Br J Pharmacol. 2011 Jun;163(3):469-83. doi: 10.1111/j.1476-5381.2011.01244.x. Br J Pharmacol. 2011. PMID: 21265827 Free PMC article. Review.
-
Gap junctions.Compr Physiol. 2012 Jul;2(3):1981-2035. doi: 10.1002/cphy.c110051. Compr Physiol. 2012. PMID: 23723031 Free PMC article. Review.
-
Connexins in the Heart: Regulation, Function and Involvement in Cardiac Disease.Int J Mol Sci. 2021 Apr 23;22(9):4413. doi: 10.3390/ijms22094413. Int J Mol Sci. 2021. PMID: 33922534 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous